ArticleFrontiers in medicine2026
Clinical efficacy analysis of platelet-rich plasma combined with Xianling Gubao Capsules in the treatment of early-middle stage knee osteoarthritis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the clinical efficacy of platelet-rich plasma (PRP) combined with Xianling Gubao Capsules in the treatment of early to moderate knee osteoarthritis (KOA, Kellgren-Lawrence grade I-III), and to explore exploratory associations with serum levels of transforming growth factor-β1 (TGF-β1) and Smad-1, thereby providing clinical and mechanistic evidence for an integrated traditional Chinese and Western medicine approach in managing early-moderate KOA. Methods: A total of 60 patients with early to moderate KOA admitted to Gaoyou People's Hospital between January 2024 and January 2025 were enrolled in this single-center, prospective, randomized controlled trial (RCT) and randomly assigned to a control group ( Results: All patients completed follow-up. The clinical effective rate was 96.7% in the study group and 90.0% in the control group, with no statistically significant difference ( Conclusion: Platelet-rich plasma combined with Xianling Gubao Capsules effectively alleviates pain and improves joint function in patients with early to moderate KOA, with superior efficacy compared to PRP alone. Exploratory serum biomarker findings suggest potential associations with downregulation of TGF-β1 and upregulation of Smad-1, which may be linked to inhibited joint inflammation and promoted cartilage repair. The combined regimen is safe and does not increase the risk of adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.